Sandoz Mulls At-Risk Launch For US Natalizumab
Also Provides Detailed Update On US Adalimumab And Wider Biosimilars Business
• By David Wallace
Sandoz is considering whether to launch its Tyruko natalizumab biosimilar ‘at risk’ in the US • Source: Shutterstock 
